 |
|
 |
Pipeline |
|
|
IRIS International, Inc. Product Pipeline Analysis
Publication Date August 2008
Publisher Global Markets Direct
Product Type Report
Pages 58
ISBN Number not applicable
Product Code GMD660
|
|
|
Summary
This report is an insightful source for data, analysis and strategic insights into a IRIS International, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.
Scope
- Details of development stage by sector and equipment type.
- Pipeline products grouped by therapy area, development stage and trial phase.
- Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
- Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
- Product updates covering estimated approval dates and estimated launch dates.
- Descriptions of novel technologies relating to pipeline products of the company.
- Patents and patent applications covered for the product.
- News updates on key events relating to the product and its development.
Reasons to buy
- A single source to fulfill competitor information relating to products in development.
- Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
- Access clinical trial information to map trial results and plan targeted marketing activities.
- Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
- Identification of potential investment opportunities.
- Build up knowledge base for potential distribution and marketing partners.
- Helps avoid patent infringement.
- Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.
|
Content
- 1 List of Tables
- 2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook - In Vitro Diagnostics
- 3 Business Description
- 3.1 Business Overview
- 3.2 Major Products and Services
- 4 History
- 5 Competitors
- 6 Key Employees
- 7 Key Employee Biographies
- 8 Company Statement
- 9 Locations And Subsidiaries
- 9.1 Head Office
- 9.2 Other Locations & Subsidiaries
- 10 Recent Developments
- 10.1 Strategy And Business Planning
- 10.1.1 May 22, 2007: IRIS International Announces Closing Of Its Subsidiary
- 10.2 Financial Announcements
- 10.2.1 Jul 28, 2008: IRIS International Declares 2Q 2008 Results
- 10.2.2 Apr 29, 2008: IRIS International Declares Q1 2008 Results
- 10.2.3 Apr 14, 2008: IRIS International To Declare Q1 2008 Results
- 10.2.4 Feb 26, 2008: IRIS International Declares Q4 2007 Results
- 10.2.5 Nov 01, 2007: IRIS International Declares Q3 2007 Results
- 10.2.6 Aug 13, 2007: IRIS International Declares Q2 2007 Results
- 10.2.7 May 09, 2007: IRIS International Reports Q1 2007 Results
- 10.2.8 Mar 07, 2007: IRIS International Reports Q4 And 2006 Results
- 10.2.9 Nov 14, 2006: IRIS International Reports Q3 2006 Results
- 10.2.10 Aug 02, 2006: IRIS International Reports Q2 2006 Results
- 10.2.11 May 09, 2006: IRIS International Reports Q1 2006 Results
- 10.3 Corporate Communications
- 10.3.1 Jul 31, 2008: IRIS International Elects New Board Member
- 10.3.2 Nov 19, 2007: IRIS Elects Chairman
- 10.3.3 Mar 05, 2007: IRIS International Appoints New President
- 10.3.4 May 02, 2006: IRIS International Appoints New CFO
- 10.3.5 May 02, 2006: IRIS International CFO Retires
- 10.3.6 Apr 06, 2006: IRIS International Appoints New Director
- 10.4 Product News
- 10.4.1 Apr 18, 2008: IRIS International Presents Study Results Of Its Investigational NADiA PSA Assay
- 10.4.2 Apr 18, 2008: IRIS International, Inc. Achieves CE Mark For Its iChem VELOCITY Automated Urine Chemistry Analyzer
- 10.4.3 Feb 26, 2008: IRIS International Announces Successful Completion Of Retrospective Study Using NADiA PSA Assay
- 10.4.4 Dec 19, 2007: Iris Submits 510(K) Application To FDA For Its iCHEM Velocity Automated Urine Chemistry Analyzer
- 10.4.5 Sep 17, 2007: Iris To Commence Shipping iCHEM VELOCITY Automated Urine Chemistry Analyzer In 1st Quater 2008
- 10.4.6 Jul 13, 2007: Iris Expects Continued Strong Growth With Broadening Of Urinalysis Market And Development Of INew Products n Molecular Diagnostics And Hematology
- 10.4.7 Feb 07, 2007: IRIS Submits 510(K) Application To FDA For Its N.A.D.I.A. Prostate Cancer Test
- 10.5 Product Approvals
- 10.5.1 Apr 18, 2008: IRIS International, Inc. Achieves CE Mark For Its iChem VELOCITY Automated Urine Chemistry Analyzer
- 10.6 Clinical Trials
- 10.6.1 Apr 18, 2008: IRIS International Presents Study Results Of Its Investigational NADiA PSA Assay
- 10.6.2 Feb 26, 2008: IRIS International Announces Successful Completion Of Retrospective Study Using NADiA PSA Assay
- 11 IRIS International, Inc. Pipeline Products
- 11.1 IRIS International, Inc. Product Pipeline Analysis
- 11.1.1 IRIS International, Inc. Pipeline Products By Equipment Type
- 11.1.2 IRIS International, Inc. Pipeline Products By Development Stage
- 11.1.3 IRIS International, Inc. Pipeline Products By Therapy Area
- 11.1.4 IRIS International, Inc. Pipeline Products By Clinical Trials
- 11.1.5 IRIS International, Inc. Pipeline Products By News Summary
- 11.2 iChem VELOCITY Automated Urine Chemistry Analyzer
- 11.2.1 Product Description
- 11.2.2 Product Status
- 11.2.3 Product Milestone
- 11.3 NADIA - HIV
- 11.3.1 Product Description
- 11.3.2 Product Status
- 11.4 NADIA PSA
- 11.4.1 Product Description
- 11.4.2 Product Status
- 11.4.3 Clinical Trials
- 11.4.4 Product Milestone
- 11.5 Bubble Isolation-Bacteria
- 11.5.1 Product Description
- 11.5.2 Product Status
- 11.6 Circulating Epithelial Cells
- 11.6.1 Product Description
- 11.6.2 Product Status
- 11.7 Blood-based Her-2/neu Test
- 11.7.1 Product Description
- 11.7.2 Product Status
- 11.8 Prostate-Specific Antigen test
- 11.8.1 Product Description
- 11.8.2 Product Status
- 11.8.3 Product Milestone
- 11.9 HIV Viral Load
- 11.9.1 Product Description
- 11.9.2 Product Status
- 11.10 NADIA Breast
- 11.10.1 Product Description
- 11.10.2 Product Status
- 11.11 Bacteriuria NP
- 11.11.1 Product Description
- 11.11.2 Product Status
- 11.12 NADIA CEC
- 11.12.1 Product Description
- 11.12.2 Product Status
- 11.13 3 GM Hematology
- 11.13.1 Product Description
- 11.13.2 Product Status
- 12 Appendix
- 12.1 Methodology
- 12.1.1 Coverage
- 12.1.2 Secondary Research
- 12.1.3 Primary Research
- 12.1.4 Expert Panel Validation
- 12.2 Contact Us
- 12.3 About Global Markets Direct
- 12.4 Disclaimer
- 1 List of Tables
- Table 1: IRIS International, Inc.,Key Facts
- Table 2: IRIS International, Inc., Key Employees,
- Table 3: IRIS International, Inc., Subsidiaries
- Table 4: IRIS International, Inc. Pipeline Products by Equipment Type
- Table 5: IRIS International, Inc. Pipeline Products By Development Stage
- Table 6: IRIS International, Inc. Pipeline Products By Therapy Area
- Table 7: IRIS International, Inc. Pipeline Products By Clinical Trials
- Table 8: IRIS International, Inc. Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: IRIS International, Inc. Pipeline Products By Equipment Type
- Figure 2: IRIS International, Inc. Pipeline Products By Equipment Type
- Figure 3: IRIS International, Inc. Pipeline Products By Development Stage
- Figure 4: IRIS International, Inc. Pipeline Products By News Summary
- Figure 5: Global Markets Direct Methodology
|
|
| Scope |
Expert Insight/Opinion |
|
| Profiles |
In-depth Company Insight |
|
| Features |
Primary Research Data |
|
|
